Mesoblast shares jump 19.7% on strong Ryoncil revenue
Alpha Vantage · grafa.com · · AI-summarised by FinFlash
Mesoblast (ASX:MSB) shares rose 19.7% after first-quarter Ryoncil net revenue climbed 44% year on year to US$28 million. Growth was driven by record new patient starts and the start of registration trials for adult patient expansion. The company held US$99 million in cash, well above the prior year.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.